Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea.
10.9758/cpn.2017.15.2.177
- Author:
Young Sup WOO
1
;
In Hee SHIM
;
Sang Yeol LEE
;
Dae Bo LEE
;
Moon Doo KIM
;
Young Eun JUNG
;
Jonghun LEE
;
Seunghee WON
;
Duk In JON
;
Won Myong BAHK
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Aripiprazole;
Prescribing pattern;
Initial dose
- MeSH:
Aripiprazole*;
Asian Continental Ancestry Group;
Diagnostic and Statistical Manual of Mental Disorders;
Hospitalization;
Hospitals, University;
Humans;
Inpatients*;
Korea*;
Medical Records;
Mental Disorders;
Psychomotor Agitation;
Retrospective Studies
- From:Clinical Psychopharmacology and Neuroscience
2017;15(2):177-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Although aripiprazole has been widely used to treat various psychiatric disorders, little is known about the adequate dosage for Asian patients in clinical practice. Hence, we evaluated the initial and maximum doses of aripiprazole from 2004 to 2014 to estimate the appropriate dosage for Korean psychiatric inpatients in clinical practice. METHODS: In this retrospective study, we reviewed the medical records of patients who were hospitalized in five university hospitals in Korea from March 2004 to December 2014. The psychiatric diagnosis according to the text revision of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition during index hospitalization and the initial and maximum doses of aripiprazole were evaluated. RESULTS: There were 74 patients in Wave 1 (2004–2006), 201 patients in Wave 2 (2007–2010), and 353 patients in Wave 3 (2011–2014). The initial doses of aripiprazole in all diagnostic groups were significantly lower in Wave 3 than in Wave 2. The maximum doses of aripiprazole in each diagnostic group were not significantly different among Waves 1, 2, and 3. CONCLUSION: The relatively low initial doses of aripiprazole documented in our study may reflect a strategy by clinicians to minimize the side effects associated with aripiprazole use, such as akathisia.
